Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Skp1-Cullin 1-F-box protein beta-transducin repeat-containing protein (SCFβTRCP) E3 ubiquitin ligase complex is a multi-protein machinery essential for the selective degradation of regulatory proteins via the ubiquitin-proteasome system [1]. It belongs to the Cullin-RING ligase (CRL) family and is composed of four core subunits: Cullin 1 (CUL1), S-phase kinase-associated protein 1 (SKP1), Ring-box protein 1 (RBX1), and the F-box protein β-TRCP (either β-TRCP1/FBXW1 or β-TRCP2/FBXW11), which acts as the substrate recognition component [2]. The complex specifically recognizes substrates containing a conserved DSG(X)2+S phosphodegron motif, such as IκBα, β-catenin, and CDC25A [3]. By regulating the levels of these proteins, SCFβTRCP controls critical cellular processes including the NF-κB and Wnt signaling pathways, cell cycle progression, and apoptosis [4]. In human diseases, its dysregulation is frequently observed in various cancers, where it can function as an oncoprotein by degrading tumor suppressors or as a tumor suppressor by degrading oncoproteins [5]. Therapeutic strategies targeting this complex include the development of small-molecule inhibitors to stabilize its substrates and the design of Proteolysis Targeting Chimeras (PROTACs) that hijack the complex to degrade specific neo-substrates [6].
The complex functions as an E3 ubiquitin ligase that facilitates the polyubiquitination of specific phosphorylated substrates, marking them for degradation by the 26S proteasome [1, 2].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Skp1-Cullin 1-F-box protein beta-transducin repeat-containing protein E3 ubiquitin ligase complex (SCF(beta-TRCP)).